Cyclophosphamide therapy for lupus nephritis: poor renal survival in Arab children

Area of Science:

• Pediatric Nephrology
• Rheumatology
• Immunosuppressive Therapy

Background:

• Limited published data exist on high-dose intravenous pulse cyclophosphamide for pediatric lupus nephritis.
• Long-term efficacy and safety of this treatment remain largely uncharacterized.

Purpose of the Study:

• To prospectively evaluate the 5-year clinical efficacy and safety of high-dose intravenous pulse cyclophosphamide in children with severe lupus nephritis.

Main Methods:

• Nine children with severe active lupus nephritis received monthly intravenous cyclophosphamide pulses (0.75-1 g/m(2)) for 6 months, followed by quarterly pulses for 36 months.
• Patients were followed prospectively for 5 years.

Main Results:

• Cyclophosphamide treatment demonstrated significant improvement in renal function during the therapy period.
• However, 56% of patients progressed to chronic renal failure, and 22% required dialysis within 2 years post-therapy.
• High initial serum creatinine and hypertension were associated with poorer long-term outcomes.

Conclusions:

• The studied regimen of intravenous high-dose pulse cyclophosphamide appears ineffective for long-term lupus nephritis management in children.
• This treatment approach may not prevent disease progression to end-stage renal disease, particularly in patients with severe initial presentation.